Equine proBNP antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Equine proBNP antibodies pairs and antigen for animal health (animal Equine/Horse intrinsic cardiac dysfunction) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine disease testing products collection >>

Product information

Size： 1mg | 10mg | 100mg

Product Description

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker Information

B-type natriuretic peptide (BNP) is a cardiac hormone that plays a key role in regulating the cardiovascular system. It is primarily secreted by the ventricles of the heart in response to increased wall stress and stretch, which are often associated with conditions like heart failure or cardiac overload. BNP acts as a vasodilator, meaning it helps to widen blood vessels, and promotes diuresis, which increases the excretion of salt and water through urine. These actions help reduce the workload of the heart and alleviate the symptoms of cardiac dysfunction.

In horses, proBNP is the inactive precursor of BNP and is synthesized and stored in cardiomyocytes, the heart muscle cells. When the heart undergoes excessive stretching or pressure overload, such as in cases of myocardial dysfunction or valvular diseases, proBNP is cleaved into its active form, BNP. This cleavage process is catalyzed by an enzyme called corin. Once released into the bloodstream, BNP acts on receptors in various tissues, including blood vessels and the kidneys, exerting its physiological effects.

The production and release of proBNP and BNP are tightly regulated processes. Multiple factors influence their synthesis, including mechanical stress on the heart, neurohormonal factors, and genetic variations. For example, increased wall stress due to an enlarged heart or high blood pressure triggers the release of proBNP, which then undergoes enzymatic cleavage to produce active BNP. On the other hand, conditions such as low blood pressure or dehydration can decrease the synthesis and secretion of proBNP and BNP.

Researchers have identified specific proBNP fragments that exhibit differential expression patterns in various cardiac conditions. By measuring the levels of these fragments, veterinarians can gain a more comprehensive understanding of the underlying cardiac pathology. For instance, in horses with congestive heart failure, elevated proBNP levels indicate the severity of the disease and can help monitor the response to treatment. By contrast, reduced proBNP levels may signify an improvement in cardiac function.

To measure proBNP levels, advanced techniques such as immunoassays and mass spectrometry are employed. Immunoassays use specific antibodies that recognize and bind to proBNP or its fragments, allowing their quantification in a sample. Mass spectrometry is a sensitive analytical technique that can precisely measure the mass and concentration of proBNP peptides in equine plasma or serum. These methods enable accurate and reliable assessment of proBNP concentrations, aiding in the diagnosis and management of cardiac disorders in horses.

About GDU